Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTITUDE
NCT07099391Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2025
- Primary completion
- Jul 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of teclistamab in multiple myeloma (MM) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Toxicity at 4 months and Minimal Residual Disease Negativity at 6 months. Started Jul 2025; status: recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07099391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07099391.